Is Kenvue Inc. (KVUE) Overvalued?
We dive into why Kenvue Inc. (KVUE) could be considered overvalued on 2026-07-17, based on AAII’s Value Score and Grade.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Kenvue Inc. operates as a consumer health company in the United States, rest of North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates in three segments: Self Care, Skin Health and Beauty, and Essential Health. The company offers over-the-counter medicine for cough, cold and allergy, pain care, digestive health, smoking cessation, and eye care, as well as other naturally inspired and self-care products, digital diagnostics, and telemedicine; face and body care, hair, sun, and other care products; oral and baby care, women’s health, wound care, and other essential health products; tampons; cosmetics; and vitamins and supplements. It sells its products under the Benadryl, Calpol, Motrin, Nicorette, Rhinocort, Tylenol, Zarbee’s Naturals, and Zyrtec; Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Neutrogena, OGX, and Rogaine; BAND-AID, Carefree, Desitin, Johnson’s, Listerine, o.b., and Stayfree; and ORSL, Clean & Clear, Versalie, Benylin, Daktarin, Imodium, Johnson’s Baby, Johnson’s Adult, Maui Moisture, Microlax, Motilium, Neosporin, Neostrata, Pepcid, Pulmicort, Regaine, Sudafed, and Visine/Vispring/Visclear brands. Kenvue Inc. was incorporated in 2022 and is headquartered in Summit, New Jersey.
Commentary & Analysis
What You Need to Know About Kenvue Inc.'s Q2 Earnings
Kenvue Inc.'s fiscal Q2 earnings report was released on Thursday, May 07. Let's dive in to see if (KVUE) missed or beat analyst's expectations.Rosalio Madrigal
What You Need to Know About Kenvue Inc.'s Q1 Earnings
Kenvue Inc.'s fiscal Q1 earnings report was released on Tuesday, February 17. Let's dive in to see if (KVUE) missed or beat analyst's expectations.Omar Beirat
What You Need to Know About Kenvue Inc.'s Q4 Earnings
Kenvue Inc.'s fiscal Q4 earnings report was released on Monday, November 03. Let's dive in to see if (KVUE) missed or beat analyst's expectations.Tudor Pop
Why Kenvue Inc.’s (KVUE) Stock Is Up 7.06%
As of Friday, October 17, Kenvue Inc.’s KVUE share price has surged by 7.06%, which has investors questioning if this is right time to sell.Jenna Brashear
Financial Summary
| Share Statistics | KVUE | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $36,941.0 | $337.9 | 91% |
|
| Shares Out (Mil) | 1,922.0 | 27.3 | 97% |
|
| Institutional Ownership | 100.0% | 55.3% | 99% |
|
| Float (Mil) | 1,917.5 | 30.7 | 95% |
|
| Beta | 0.44 | 0.56 | 24% |
|
| Avg Daily Volume (000s) | 17,696 | 150 | 98% |
|
| Price Change (52-week) |
(11.3%) | 56.7% | 36% |
|
| Growth | KVUE | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 0.9% | 2.3% | 19% |
|
| Net Income (5yr) | 29.7% | (4.8%) | 84% |
|
| EPS (5yr) | na | 2.3% | na |
|
| Dividends (5yr) | 0.0% | 0.0% | 76% |
|
| Cash Flow (5yr) | na | (13.2%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 9 | 16 | 16 | |
| Current EPS | $0.319 | $1.179 | $1.242 | |
| Month Ago EPS | $0.318 | $1.189 | $1.237 | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | $0.306 | $1.133 | $1.199 | |
| Year/Year Chg | 29.1% | 55.1% | 73.9% | |
| Financials | KVUE | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $15,292 | $421 | 89% |
|
| Net Income (TTM) (Mil) | $1,622 | $0 | 91% |
|
| EPS (TTM) | $0.846 | $0.100 | 59% |
|
| Operating Cash Flow (TTM) (Mil) | $2,258 | $12 | 89% |
|
| Net Cash Flow (TTM) (Mil) | $18 | $0 | 62% |
|
| Long-Term Debt (Q1) (Mil) | $7,171 | $44 | 89% |
|
| Enterprise Value (Q1) (Mil) | $45,129 | $334 | 91% |
|
| Valuation | KVUE | Industry Median |
Percentile (All Stocks) |
|
| P/B | 3.48 | 2.05 | 69% |
|
| P/E | 22.9 | 16.4 | 57% |
|
| Dividend Yield | 4.4% | 0.0% | 92% |
|
| PEG (5yr hist) | na | 0.7 | na |
|
| Ratios | KVUE | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 58.6% | 64.3% | 71% |
|
| Net Margin | 10.6% | 1.6% | 65% |
|
| ROA | 6.1% | 1.3% | 77% |
|
| ROE | 15.7% | 5.3% | 73% |
|
| Liabilities to Assets | 60.5% | 48.0% | 55% |
|
| F-Score | 7 | 4 | 84% |
|
Kenvue Inc. did not pass any screens on 7/31/2026.
